Alebund gets FDA clearance for IND application for AP308 in IgA nephropathy
Alebund Pharmaceuticals said the U.S. FDA cleared its Investigational New Drug (IND) application for AP308 for the treatment of IgA nephropathy.
SHANGHAI, Sept. 8, 2026 // -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, said it recently received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New...